Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

DISEASE CHARACTERISTICS: Histologically confirmed chronic lymphocytic leukemia OR small lymphocytic lymphoma Stage III-IV OR Stage I-II, if determined to have disease progression evidenced by 1 of the following characteristics: Rapid doubling of peripheral lymphocyte count Progressive lymphadenopathy Progressive splenomegaly B symptoms Grade 2 or 3 fatigue CD23+ disease Progressive disease after at least 1 prior chemotherapy course PATIENT CHARACTERISTICS: Age 18 and over Performance status WHO 0-2 Life expectancy At least 6 months Hematopoietic Platelet count at least 50,000/mm^3 Hepatic Bilirubin no greater than 2.0 mg/dL AST/ALT no greater than 1.5 times upper limit of normal (ULN) Renal Creatinine no greater than 1.5 times ULN Cardiovascular No New York Heart Association class III or IV cardiac disease No myocardial infarction within the past 6 months No unstable arrhythmia No evidence of ischemia on EKG within the past 14 days Pulmonary FEV_1 at least 60% of predicted DLCO at least 55% of predicted Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study treatment HIV negative No secondary malignancy requiring active treatment (except hormonal therapy) No serious nonmalignant disease that would preclude study participation No active uncontrolled bacterial, viral, or fungal infection No clinically active autoimmune disease PRIOR CONCURRENT THERAPY: Biologic therapy More than 4 weeks since prior anticancer biologic therapy More than 4 weeks since prior anticancer radioimmunotherapy No prior exposure to IDEC-152 or anti-CD23 antibodies Chemotherapy See Disease Characteristics More than 4 weeks since prior anticancer chemotherapy Endocrine therapy Concurrent hormonal therapy allowed for second malignancy Radiotherapy More than 4 weeks since prior anticancer radiotherapy Surgery More than 4 weeks since prior major surgery (except for diagnostic surgery) Other More than 4 weeks since prior anticancer investigational therapy No other concurrent anticancer therapy